Health Care/Hospital
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challen...
2026-03-24 20:00
3413
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
2026-03-24 19:44
4698
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...
2026-03-24 18:29
3776
GCCL Showcases RSV FRNT Research and Integrated Bioanalytical Capabilities at World Vaccine Congress 2026
YONGIN, South Korea, March 24, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a global clinical trial laboratory services provider, announced that it will attend World Vaccine Congress 2026 (WVC 2026), taking place from March 30 to April 2 in Washington, D.C., where it will operate an exhibition boo...
2026-03-24 17:35
3442
Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...
2026-03-24 17:24
4441
DualityBio (9606.HK) Announces 2025 Annual Results
HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...
2026-03-24 15:55
4596
HD Hyundai Conducts Large-Scale Medical Mission in Subic, Philippines
* Medical staff from Ulsan University Hospital and employees of HD Hyundai Heavy Industries Philippines provide care to about 750 local residents * HD Hyundai operates a shipyard in Subic and participates in the Philippine Navy's modernization program SEOUL, South Korea, March 24, 2026 /PRNews...
2026-03-24 15:15
4432
Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study ev...
2026-03-24 11:32
4208
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...
2026-03-24 10:44
5036
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
SUZHOU, China, March 24, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination with albumin-bound docetaxel (HB1801) and chemothe...
2026-03-24 09:32
5918
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
* 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharma...
2026-03-24 08:00
4713
Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phas...
2026-03-24 05:30
3976
Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Peer-reviewed economic analysis finds a combined ESR + CRP testing strategy
reduces misdiagnoses and delivers net cost savings compared to CRP alone
SMITHFIELD, R.I., March 24, 2026 /PRNewswire/ --
2026-03-24 04:32
4329
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with expansion plans underway HONG KONG, March 23, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company"...
2026-03-23 22:56
6639
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
* Revenue increased by 46.7% YoY to RMB 5,944 million * Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 * Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percen...
2026-03-23 21:15
5829
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begi...
2026-03-23 21:00
6977
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
5160
Cambrex Advances US and European Expansions
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles ...
2026-03-23 20:00
5037
Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
MELBOURNE, Australia, March 23, 2026 /PRNewswire/ -- Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring ground...
2026-03-23 14:15
5569
Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
SHANGHAI, March 23, 2026 /PRNewswire/ -- Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational pr...
2026-03-23 14:02
6988
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7344
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7249
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6490
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6398
